Cargando…
Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials
OBJECTIVE: Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604726/ https://www.ncbi.nlm.nih.gov/pubmed/28955499 http://dx.doi.org/10.1136/rmdopen-2017-000496 |
_version_ | 1783264910567800832 |
---|---|
author | Strand, Vibeke Michalska, Margaret Birchwood, Christine Pei, Jinglan Tuckwell, Katie Finch, Rebecca Gabay, Cem Kavanaugh, Arthur Jones, Graeme |
author_facet | Strand, Vibeke Michalska, Margaret Birchwood, Christine Pei, Jinglan Tuckwell, Katie Finch, Rebecca Gabay, Cem Kavanaugh, Arthur Jones, Graeme |
author_sort | Strand, Vibeke |
collection | PubMed |
description | OBJECTIVE: Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit of TCZ versus MTX or ADA monotherapy for improving patient-reported outcomes (PROs) in patients with RA. METHODS: PROs included patient global assessment (PtGA), pain, Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and Short Form-36 (SF-36) physical component summary (PCS) and mental component summary (MCS) and eight domain scores. Outcomes included proportions of patients reporting changes from baseline in PRO scores ≥minimum clinically important differences (MCID) and ≥age-matched and gender-matched normative values at 24 weeks. RESULTS: In AMBITION, TCZ-treated patients reported significantly greater mean improvements in HAQ (−0.7 vs −0.5), FACIT-Fatigue (8.7 vs 5.7), SF-36 PCS (9.8 vs 7.8) and five SF-36 domains at week 24 than with MTX; 45.0%–84.0% of TCZ-treated patients reported improvements ≥MCID, and 24.3%–52.1% reported scores ≥normative values across all PROs versus 39.4%–81.8% and 14.5%–45.0%, respectively, with MTX. In ADACTA, TCZ-treated patients reported significantly greater improvements in PtGA (−42.3 vs −31.8), pain (−40.1 vs −28.7), SF-36 MCS (7.9 vs 5.0) and three SF-36 domains than with ADA; 57.7%–83.3% of TCZ-treated patients reported improvements ≥MCID, and 22.1%–49.3% reported scores ≥normative values across all PROs versus 13.6%–37.8%, respectively, with ADA. CONCLUSIONS: TCZ monotherapy resulted in more patients reporting clinically meaningful PRO improvements and PRO scores ≥normative values compared with MTX or ADA monotherapy. TRIAL REGISTRATION NUMBERS: NCT00109408 and NCT01119859; Post-results. |
format | Online Article Text |
id | pubmed-5604726 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-56047262017-09-27 Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials Strand, Vibeke Michalska, Margaret Birchwood, Christine Pei, Jinglan Tuckwell, Katie Finch, Rebecca Gabay, Cem Kavanaugh, Arthur Jones, Graeme RMD Open Rheumatoid Arthritis OBJECTIVE: Two randomised controlled trials, AMBITION (NCT00109408) and ADACTA (NCT01119859), showed tocilizumab (TCZ) monotherapy superior to methotrexate (MTX) and adalimumab (ADA) monotherapy, respectively, for improving rheumatoid arthritis (RA) disease activity. This study compared the benefit of TCZ versus MTX or ADA monotherapy for improving patient-reported outcomes (PROs) in patients with RA. METHODS: PROs included patient global assessment (PtGA), pain, Health Assessment Questionnaire Disability Index (HAQ-DI), Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue and Short Form-36 (SF-36) physical component summary (PCS) and mental component summary (MCS) and eight domain scores. Outcomes included proportions of patients reporting changes from baseline in PRO scores ≥minimum clinically important differences (MCID) and ≥age-matched and gender-matched normative values at 24 weeks. RESULTS: In AMBITION, TCZ-treated patients reported significantly greater mean improvements in HAQ (−0.7 vs −0.5), FACIT-Fatigue (8.7 vs 5.7), SF-36 PCS (9.8 vs 7.8) and five SF-36 domains at week 24 than with MTX; 45.0%–84.0% of TCZ-treated patients reported improvements ≥MCID, and 24.3%–52.1% reported scores ≥normative values across all PROs versus 39.4%–81.8% and 14.5%–45.0%, respectively, with MTX. In ADACTA, TCZ-treated patients reported significantly greater improvements in PtGA (−42.3 vs −31.8), pain (−40.1 vs −28.7), SF-36 MCS (7.9 vs 5.0) and three SF-36 domains than with ADA; 57.7%–83.3% of TCZ-treated patients reported improvements ≥MCID, and 22.1%–49.3% reported scores ≥normative values across all PROs versus 13.6%–37.8%, respectively, with ADA. CONCLUSIONS: TCZ monotherapy resulted in more patients reporting clinically meaningful PRO improvements and PRO scores ≥normative values compared with MTX or ADA monotherapy. TRIAL REGISTRATION NUMBERS: NCT00109408 and NCT01119859; Post-results. BMJ Publishing Group 2017-09-14 /pmc/articles/PMC5604726/ /pubmed/28955499 http://dx.doi.org/10.1136/rmdopen-2017-000496 Text en © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted. This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Rheumatoid Arthritis Strand, Vibeke Michalska, Margaret Birchwood, Christine Pei, Jinglan Tuckwell, Katie Finch, Rebecca Gabay, Cem Kavanaugh, Arthur Jones, Graeme Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
title | Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
title_full | Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
title_fullStr | Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
title_full_unstemmed | Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
title_short | Impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
title_sort | impact of tocilizumab monotherapy on patient-reported outcomes in patients with rheumatoid arthritis from two randomised controlled trials |
topic | Rheumatoid Arthritis |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5604726/ https://www.ncbi.nlm.nih.gov/pubmed/28955499 http://dx.doi.org/10.1136/rmdopen-2017-000496 |
work_keys_str_mv | AT strandvibeke impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT michalskamargaret impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT birchwoodchristine impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT peijinglan impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT tuckwellkatie impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT finchrebecca impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT gabaycem impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT kavanaugharthur impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials AT jonesgraeme impactoftocilizumabmonotherapyonpatientreportedoutcomesinpatientswithrheumatoidarthritisfromtworandomisedcontrolledtrials |